Thimerosal: Chemistry, toxicology and effects on biological systems

Autism Research Advances

Volumn , Issue , 2007, Pages 137-168

  White, John F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955648900     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (149)

1. Blaxill, MF; Redwood, L; Bernard,S. Thimerosal and autism? A plausible hypothesis that should not be dismissed. Med. Hypotheses 2004 62, 788-794.
2. Ball, LK; Ball, R; Pratt, RD. An assessment of thimerosal use in childhood vaccines. Pediatrics 2001 107, 1147-1154.
3. Geier, DA; Geier, MR. A two-phased population epidemiological study of the safety of thimerosal-containing vaccines: a follow-up analysis. Med. Sci. Monit. 2005 11, 160-170.
4. Geier, DA; Geier, MR. Early downward trends in neurodevelopmental disorders following removal of thimerosal-containing vaccines. J. Am. Physicians and Surgeons.2006 11, 8-14.
5. Elferink, JGR. Thimerosal A versatile sulfhydryl reagent, calcium mobilizer, and cell function-modulating agent. Gen. Pharmacol. 1999 33, 1-6.
6. Risher, JF; Murray, HE; Prince, GR. Organic mercury compounds: human exposure and its relevance to public health. Toxicol and Ind. Health 2002 18, 109-160.
7. Magos, L. Review on the toxicity of ethylmercury, including its presence as a preservative in biological and pharmaceutical compounds. J. Appl. Toxicol. 2001 21, 1-5.
8. Clarkson, TW. The three modern faces of mercury. Environmental Health Perspectives 2002 110, 11-23.
9. Dinehart, SM; Dillard, R; Raimer, SS; Diven, S; Cobos, R; Pupo, R. Cutaneous manifestations of acrodynia (pink disease). Arch. Dermatol 1988 124, 107-109.
10. Tan, M; Parkin, JE. Route of decomposition of thiomersal (thimerosal). Int. J. Pharmaceutics. 2000 208, 23-34.
11. Qvarnstrom, J; Lambertsson, L; Havarinasab, S; Hultman, P; Frech, W. Determination of methylmercury, ethylmercury, and inorganic mercury in mouse tissues, following administration of thimerosal, by species-specific isotope dilution GC-inductively coupled plasma-MS. Analytical Chemistry 2003 75, 4120-4124.
12. Reader, MJ; Lines, CB. Decomposition of thimerosal in aqueous solution and its determination by high-performance liquid chromatography. J. Pharmaceutical Sciences 1983 72, 1406-1409.
13. Camera, E; Cannistraci, C; Santucci,A; Picardo,B. Studies on the mechanism of thimerosal sensitivity. Int J Immunopathology, Pharmacol 1997 10, 49-51.
14. Westphal, GA; Asgari, S; Schulz, TG; Bunger, J; Muller, M; Hallier, E. Thimerosal induces micronuclei in the cytochalasin B-block micronucleus test with human lymphocytes, Arch. Toxicol. 2003, 33, 50-55.
15. Reader, MJ. Influence of isotonic agents on the stability of thimerosal in ophthalmic formulations. J. Pharm. Sci. 1984 73, 840-841.
16. Caraballo, I; Rabasco, AM; Fernandez-Arevalo, M. Study of thimerosal degradation mechanism. Int. J. Pharm. 1993 89, 213-221.
17. Rabasco, AM; Caraballo, M; Fernandez-Arevalo, M. Formulation factors affecting thimerosal stability. Drug Dev. Ind. Pharm. 1993 19, 1673-1693.
18. Faridah, MC; Parkin JE. The effect of disodium acetate and sodium chloride on the stability of ethylmercury arising from the decomposition of thimerosal (thiomersal). Drug Dev. Ind. Pharm. 1995 21, 2403-2410.
19. Perez-Barrales, MJ; Caraballo, J; Rabasco, AM. Kinetic study of thiomersal degradation products. Pharmazie 1997 52, 453-454.
20. Parkin, JE. Assay of thiomersal (thimerosal) with adaptation to the quantitation of total ethylmercury available in degraded samples. J. Chromatogr. 1991 587, 329-332.
21. Davies, DJG; Anthony, Y; Meakin, BJ. The antimicrobial activity of degraded thiomersal solutions. Expo. Congr.Int. Technol. Pharm. 1983 4, 238-242.
22. Engst, S; Miller, SM. Rapid reduction of Hg(II) by mercuric ion reductase does not require the conserved C-terminal cysteine pair using HgBr2 as the substrate. Biochemistry 1998 37, 11496-11507.
23. Suda, I; Totoki, S; Uchida,T; Takahashi,H. Degradation of methyl and ethyl mercury into inorganic mercury by various phagocytic cells. Arch Toxicol 1992 66, 40-44.
24. Suda, I; Hirayama, K. Degradation of methyl and ethyl mercury into inorganic mercury by hydroxyl radical produced from rat liver microsomes, Arch Toxicol 1992, 66, 398-402.
25. Clarkson, TW. The toxicology of mercury. Critical Reviews in Clinical Laboratory Sciences. 1997 34, 369-403.
26. Rabenstein, DL. The aqueous solution chemistry of methylmercury and its complexes. Acc. Chem. Re.s 1978 11, 100-107.
27. Dogar, V; Sokhey, J; Kumar, S; Sood, DK; Tahlan, AK. Interference of thiomersal in biologicals during protein estimation. Biologicals 2002 30, 271-275.
28. Chattaraj, SC; Das, SK. Interference of thimerosal in the bicinchoninc acid protein microassay. Bolletino Chimico Farmaceutico 2000 139, 30-33.
29. Cleland, WW. Dithiothreitol, a new protective reagent for SH groups. Biochemistry 1964 3, 480-482.
30. Song, JH; Yang, YY; Shin,YK; Lee, MY; Lee, C-S. Inhibitory action of thimerosal, a sulfhydryl oxidant, on sodium channels in rat sensory neurons. Brain Res. 2000 864, 105-113.
31. Bannister, JPA; Young,BA; Main,MJ; Sovaprasadarao,A;Wray,D. The effects of oxidizing and cysteine-reactive reagents on the inward rectifier potassium channels Kir. 3 and Kir1. 1. Pflugers Arch-Eur. J. Physiol. 1999 438, 868-878.
32. Pintado, E; Baquero-Leonis, D; Conde, M; Sobrino, F. Effect of thimerosal and other sulfhydryl reagents on calcium permeability in thymus lymphocytes. Biochem. Pharmacol., 1995 49, 227-232.
33. Eager, KH; Dulhunty,AF. Cardiac ryanodine receptor activity is altered by oxidizing reagents in either the luminal or cytoplasmic solution. J. Memb. Biol. 1999 167, 205-214.
34. Aschner, M; Aschner, JL. Mercury neurotoxicity: mechanisms of blood-brain barrier transport, Neurosci Biobehav Rev 1990, 14, 169-176.
35. Miura, K; Naganuma,A; Himeno, S; Imura,N. Mercury toxicity. In: Goyer A, Cherian, G, editors. Toxicology of metals: biochemical aspects. Berlin-Heidelberg: Springer-Verlag 1995; 163-188.
36. van Gorp, RMA; van Dam-Mieras, MCE; Hornstra, G; Heemskerk,JWM. Effect of membrane-permeable sulfhydryl reagents and depletion of glutathione on calcium mobilization in human platelets. Biochem. Pharmacol. 1997 53, 1533-1542.
37. Santucci, B; Cannistraci, C; Cristaudo, A; Camera, E; Picardo, M. Thimerosal positivities: the role of organomercury alkyl compounds. Contact Dermatitis 1998 38, 325-328.
38. Vahter, M; Mottet, NK; Friberg, L; Lind, B; Shen, D; Burbacher, T. Speciation of mercury in the primate blood and brain following long-term exposure to methylmercury. Toxicol Appl Pharmacol 1994 124, 221-229.
39. Simmons-Willis, TA; Koh, AS; Clarkson, TW; Ballatori, N. Transport of a neurotoxicant by molecular mimicry: the methylmercury-L-cysteine complex is a substrate for human L-type large neutral amino acid transporter (LAT) 1 and LAT2. Biochem. J. 2002 367, 239-246.
40. Mokrzan, EM; Kerper, LE; Ballatori, N; Clarkson,TW. Methylmercury-thiol uptake into cultured brain capillary endothelial cells on amino acid system L. J. Pharm.Exp. Therapeutics. 1995 272, 1277-1284.
41. U.S. Food and Drug Administration. Center for Biologics Evaluation and Research. Thimerosal in vaccines. What is thimerosal? 2006.
42. http://www.fda.gov/cber/vaccine/thimfaq.htm#q3.
43. Pichichero, T; Loprieato, J; Cernichiari, E; Treanor, J. Mercury concentrations and metabolism in infants receiving vaccines containing thimerosal: a descriptive study. Lancet 2002 360, 1737-1741.
44. Merck Veterinary Manual. Vol 3. Merck and Co. Inc. Whitehouse Station. N.J. USA.
45. Afrasayab, S; Yazmin, A; Hasnain, S. Characterization of some indigenous mercury resistant bacteria from polluted environment. Pakistan J. of Biological Sciences. 2002 5, 792-797.
46. Porter, FD; Silver, S; Ong,C; Nakahara,H. Selection of mercurial resistance in hospital settings. Antimicrobial Agents and Chemotherapy. 1982 22, 852-858.
47. King, JK; Kostka, JE; Frischer, ME; Saunder, FM; Jahnke, JA. Sulfate reducing bacteria methylate mercury at variable rates in pure cultures and in marine sediments. Appl. Env. Microbiol. 2000 66, 2430-2437.
48. Benoit, JM; Gilmour, CC; Mason, RP; Hayes, A. Aspects of bioavailability of mercury for methylation in pure cultures of Desulfobulbus proprionicus. Appl. Environ. Microbiol. 2001 67, 51-58.
49. Tleugabulova, D; Perez, IG. Reversed-phase high performance liquid chromatographic study of thimerosal stability in Cuban recombinant hepatitis B vaccine. J. Chromatography A 1996 729, 219-227.
50. Abuqaddom, AI; Darwish, RM; Muti, H. The effects of some formulation factors in ophthalmic preparations on thiomersal activity against Pseudomonas aeruginosa and Staphylococcus aureus. J. Appl. Microbiology 2003 95, 250-255.
51. Gotelli, CA; Astolfi, E; Cox, C; Cernichiari, E; Clarkson, TW. Early biochemical effects of an organic mercury fungicide on infants: "Dose makes the Poison". Science 1985 227, 638-640.
52. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Mercury compounds in drugs and foods. 2001
53. http://www.fda.gov/cder/fdama/mercuryreport.htm
54. Fortunato, R; Crespo, JG; Reis, MA. Biodegradation of thiomersal containing effluents by a mercury resistant Pseudomonas putida strain. Water Research 2005, 39 3511-3522.
55. Royhans, J; Walson, PD; Wood, GA; McDonald, WA. Mercury toxicity following merthiolate ear irrigations. J. Pediatrics 1984 104, 311-313.
56. Moller, H. All these positive tests to thimerosal. Contact Dermatitis 1994 31, 209-213.
57. Hammond, SA; Morgan, JR; Russell,AD. Comparative susceptibility of hospital isolates of gram-negative bacteria to antiseptics and disinfectants. J. Hospital Infection 1987 9, 255-264.
58. Ulfvarson, U. Distribution and excretion of some mercury compounds after long term exposure. Int. Arch. Gewerbepath. Bewerbehyg 1962 19, 412-422.
59. Hughes, WH. A physicochemical rationale for the biological activity of mercury and its compounds. Ann. NY Acad. Sci. 1957 65, 454-460.
60. Carty, AJ; Malone, SF. The chemistry of mercury in biological systems. In: Nrigau, JO editor. The biogeochemistry of mercury in the environment. Amsterdam: Elsevier/North Holland Biomedical Press; 1979; 433-479.
61. Stajich, GV; Lopez, GP; Harry, SW; Sexson, WR. Iatrogenic exposure to mercury after hepatitis B vaccination in preterm infants. J. Pediatrics 2000 136, 679-681.
62. World Health Organization: Environmental Health Criteria 1. Mercury. Geneva, United Nations Environmental Program and the World Health Organization. 1976; 75.
63. Suzuki, T; Takemoto, T-I; Kashiwazaki, H; Miyama, T. Metabolic fate of ethylmercury salts in man and animal. In: Miller MW, Clarkson TW. Editors. Mercury, Mercurials and Mercaptans. Springfield, IL: Charles C. Thomas; 1973; 209-232.
64. Matheson, DS; Clarkson, TW; Gelfand, WD. Mercury toxicity (acrodynia) induced by long-term injection of gamma globulin. J. Pediatr. 1980 97, 153-155.
65. Blair, AMJN; Clark, B; Clarke, AJ; Wood P. Tissue concentrations of mercury after chronic dosing of squirrel monkeys with thimerosal. Toxicology 1975 3, 171-176.
66. Berglund, F; Berlin, M. Risk of methyl mercury cumulation in man and mammals and the relation between body burden of methyl mercury and toxic effects. In: Miller MW; Berg CG Editors. Chemical Fallout, Current research on Persistent Pesticides, Illinois, Thomas; 1969; 258.
67. Rabenstein, DL; Evans, CA. The mobility of methylmercury in biological systems. Bioinorg. Chem. 1978 8, 107-114.
68. White, JF; Rothstein, A. The interaction of methyl mercury with erythrocytes. Toxicol Appl. Pharmacol 1973 26, 370-384.
69. Aschner, M; Eberle, NB; Kimelberg, HK. Interactions of methylmercury with rat primary astrocyte cultures: methylmercury efflux. Brain Research 1991 554, 10-14.
70. Pamphlett, R; Waley,P. Uptake of inorganic mercury by the human brain, Acta Neuropathol 1996, 92, 525-527.
71. Burbacher, TM; Shen, DD; Liberato, N; Grant,KS; Cernichiari, E; Clarkson,T. Comparion of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing thimerosal. Env. Health Perspectives 2005 113, 1015-1021.
72. Magos, L. Neurotoxic character of thimerosal and the allometric extrapolation of adult clearance half-time to infants, J. Appl. Toxicol 2003, 23, 263-269.
73. Charleston, JS; Body, RL; Mottet, NK; Vahter, ME; Burbacher, TM. Autometallographic determination of inorganic mercury distribution in the cortex of the calcarine sulcus of the monkey Macaca fascicularis following long-term subclinical exposure to methylmercury and mercuric chloride. Toxicol. Appl. Pharmacol 1995 132, 325-333.
74. Magos, L; Brown, AW; Sparrow, S; Bailey, E; Snowden, RE; Skipp, WR. The comparative toxicology of ethyl-and methyl mercury. Arch. Toxico.l 1985 57, 260-267.
75. Axton, JMH. Six cases of poisoning after a parenteral organic mercurial compound (Merthiolate). Postgraduate Medical Journal 1972 48, 417-421.
76. Padlewska, KK; Schwartz,RA. Acrodynia. 2005. Emedicine.com/derm/topic592.htm.
77. Black, J. The puzzle of pink disease. J. Royal Soc. Medicine 1999 92, 478-481.
78. Better Health Channel. Victorian Government (Australia). Pink Disease. http://www.betterhealth.vic.gov.au/bhcv2/bhcarticles.nsf/(Pages)/Pink_disease?Open Document.
79. Lowell, JA; Burgess, S; Shenoy, S; Peters, M; Howard,TK. Mercury poisoning associated with hepatitis-B immunoglobulin. Lancet 1996 347, 480.
80. Fagan, DG; Pritchard, JS; Clarkson, TW; Greenwood, MR. Organ mercury levels in infants with omphaloceles treated with organic mercurial antiseptic. Arch. Dis. Children. 1977 52, 962-964.
81. Pfab, R; Muckter, H; Roider, G; Zilker, T. Clinical course of severe poisoning with thiomersal. J. Toxicology-Clinical Toxicology. 1996 34, 453-460.
82. Nascimento, LO; Lorenzo-Filho,G; dos Santos Rocha, A. Lethal mercury poisoning due to ingestion of merthiolate. Rev. Hosp. Clin. Fac. Med. Sao. Paulo. 1990 45, 216-218.
83. Uchida, T; Naito, S; Kato, H; Hatano, I; Harashima, A; Terada,Y; Ohkawa T; Chino, F; Eto, K. Thimerosal induces toxic reaction in non-sensitized animals. Int. Arch. Allergy Immunol . 1994 104, 296-301.
84. Spyker, JM; Sparber, SB; Goldberg, AM. Subtle consequences of methylmercury exposure: behavioral deviation in offspring of treated mothers. Science 1972 177, 621-623.
85. Weiss, B; Clarkson, TW; Simon, W. Silent latency periods in methylmercury poisoning and in neurodegenerative disease. Environmental Health Perspectives. 2002 110, 851-854.
86. Jalili, MA; Abbasi, AH. Poisoning by ethyl mercury toluene sulfonamide. Gr. J. Ind. Med. 1961 18, 303-308.
87. Zhang, J. Clinical observations in ethyl mercury chloride poisoning. Am. J. Industrial Medicine 1984 5, 251-258.
88. Magos, L; Sparrow,S; Snowden,R. The comparative renotoxicology of phenylmercury and mercuric chloride. Arch, Toxicol. 1982 50, 133-139.
89. Gage, JC. Distribution and excretion of methyl and phenyl mercury salts. Br.J Ind. Med. 1964 21, 197-202.
90. Warkany ,J. Acrodynia--Postmortem of a disease. Am. J. Dis. Children 1966 112, 147-156.
91. Marsh, DO; Myers, GJ; Clarkson, TW; Amin-Zaki, L; Tikriti, S; Majeed,MA. Fetal methylmercury poisoning: clinical and toxicological data on 29 cases. Ann. Neurol. 1980 7:348-353.
92. Hornig, M; Chian,D; Lipkin,WI. Neurotoxic effects of postnatal thimerosal are mouse strain dependent. Molecular Psychiatry 2004 9, 833-845.
93. Westphal GA; Schnuch, A; Schulz, TG; Reich, K; Aberer, W; Brasch, J; Koch, J; Wessbecher, R; Szliska, C; Bauer, A; Hallier, E. Homozygous gene deletions of the glutathione S-transferase M1 and T1 are associated with thimerosal sensitization. Int. Arch. Occup. Environ. Health 2000 73, 384-388.
94. Kiec-Swierczynska, M. Allergic reaction to merthiolate (a disinfectant) based on material from the Occupational Medicine Institute in Lodz. Medycyna Pracy 1996 47, 125-131.
95. Santucci, BC; Cannistraci, A; Cristaudo, E; Camera,E; Picardo,M. Thimerosal positivities: the role of organomercury alkyl compounds. Contact Dermatitis 1998 38, 325-328.
96. Spiewak, R. Atopy and contact hypersensitivity: a reassessment of the relationship using objective measures. Ann. Allergy, Asthma and Immunology 2005 95, 61-65.
97. Schafer, TH; Bohler, J; Klemm, E; Merkl, E; Rudhorfer, J; Weigl, S; Wessner, L; Wichmann, D; Ring,HE; Monica/Kora-Studiengruppe, J. Allergies in adults. Gesundheitswesen. 2005 67 Suppl.1, S187-192.
98. Boyvat, A; Akyol, A; Gurgey,E. Contact sensitivity to preservatives in Turkey. Contact Dermatitis. 2005 52: 329-332.
99. Slodownik, D; Ingber, A. Thimerosal-is it really irrelevant? Contact Dermatitis 2005 53, 324-326.
100. Goncalo, M; Figueiredo, A; Goncalo, S. Hypersensitivity to thimerosal: the sensitizing moiety. Contact Dermatitis 1996 34, 201-203.
101. Pirker, C; Moslinger, T; Wantke,F; Gotz,M; Jarisch,R. Ethylmercuric chloride: the responsible agent in thimerosal hypersensitivity. Contact Dermatitis 1993 29, 152-154.
102. Wantke, F; Demmer,CM; Gotz,M; Jarisch,R. Contact dermatitis from thimerosal: 2 years' experience with ethylmercuric chloride in patch testing thimerosal-sensitive patients. Contact Dermatitis 1994 30, 115-117.
103. Elferink, JG; de Koster, BM. The effect of thimerosal on neutrophil migration: a comparison with the effect on calcium mobilization and CD11b expression. Biochem. Pharm 1998 55, 305-312.
104. Makani, S; Gollapudi, S; Yel, L; Chiplunkar, S; Gupta S. Biochemical and molecular basis of thimerosal induced apoptosis in T cells: a major role of mitochondrial pathway. Genes Immun., 2002 3, 270-278.
105. Seelbach, A; Fissler, B; Madle, S. Further evaluation of a modified micronucleus assay with V79 cells for detection of aneugenic effects. Mutat. Res. 1993 303, 163-169.
106. Migliore, L; Nieri, M. Evaluation of twelve potential aneuploidogenic chemicals by the in vitro human lymphocyte micronucleus assay. Toxicol In Vitro 1991 5, 325-336.
107. Marrazzini, A; Betti, C; Bernacchi, F; Barrai, I; Barale, R. Micronucleus test and metaphase analyses in mice exposed to known and suspected spindle poisons. Mutagenesis 1994 9, 505-515.
108. Adler, I D; Kliesch, U; van Hummelen, P; Kirsch-Volders, M. Mouse micronucleus tests with known and suspect spindle poisons: results from two laboratories. Mutagenesis 1991 6, 47-53.
109. Machaty, Z; Wang, WH; Day, BN; Prather,RS. Complete activation of porcine oocytes induced by the sulfyhdryl reagent, thimerosal. Biol. Reproduction 1997 57, 1123-1127.
110. Machaty, Z; Wang, WH; Day, BN; Prather,RS. Calcium release and subsequent development induced by modification of sulfhydryl groups in porcine oocytes. Biol. Reproduction 1999 60, 1384-1391.
111. Sarafian, TA; Bredesen, DE; Verity, MA. Cellular resistance to methylmercury. Neurotoxicology 1996 17, 27-36.
112. James, SJ; Slikker, W; MeInyk, S; New, E; Pobribna, M; Jernigan S. Thimerosal neurotoxicity is associated with glutathione depletion: protection with glutathione precursors. Neurotoxicology 2005 26, 1-8.
113. Dierickx, PJ. In vitro interaction of organic mercury compounds with soluble glutathione S-transferase from rat liver. Pharmacol. Res. Commun. 1985 17, 489-500.
114. Yel, L; Brown, LE; Su, K; Gollapudi, S; Gupta, S. Thimerosal induces neuronal cell apoptosis by causing cytochrome c and apotosis-inducing factor release from mitochondria. Intl. J. Mol. Medicine. 2005 16, 971-977.
115. Ueha-Ishibashi, T; Oyama, Y; Nakao, H; Umebayashi, C; Nishizaki, Y; Tatsuishi, T; Iwase, K; Murao, K; Seo H. Effect of thimerosal, a preservative in vaccines, on intracellular Ca2+ concentration of rat cerebellar neurons. Toxicology 2004 195, 77-84.
116. Faure, A-V; Grunwald, D; Moutin, M-J; Hilly, M; Mauger, J-P; Marty, I; DeWaard, M; Villaz, M; Albrieux, M. Developmental expression of the calcium release channels during early neurogenesis of the mouse cerebral cortex. European J. Neuroscience 2001 14, 1613-1622.
117. Carey, MB; Matsumoto, SG. Spontaneous calcium transients are required for neuronal differentiation of murine neural crest. Dev. Biol. 1999 215, 298-313.
118. Snider, BJ; Choi, J; Turetsky, DM; Canzoniero, LM; Sensi, SL; Sheline, CT; Wang, X; Yu, SP; Choi, DW. Nitric oxide reduces Ca(2+) and Zn(2+) influx through voltagegated Ca(2+) channels and reduces Zn(2+) neurotoxicity. Neuroscience 2000 100, 651-661.
119. Rice, D; S Jr Barone. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ. Health Perspectives 2000 108, 511-533.
120. Oyama, Y; Okazaki, E; Chikahisa, L; Nagano, T; Sadakata, C. Oxidative stressincreased in intracellular Ca2+ and Ca2+-induced increase in oxidative stress: an experimental model using dissociated rat brain neurons. Japan J Pharmacol 1996 72, 381-385.
121. Leong, CC; Syed, NI; Lorscheider,L. Retrograde degeneration of neurite membrane structural integrity of nerve growth cones following in vitro exposure to mercury. Neuroreport 2001 12, 733-737.
122. Miura, K; Imura, N. Mechanism of methyl mercury cytotoxicity. Crit. Rev. Toxicol. 1987 18, 161-188.
123. Jellerette, T; He, CL; Wu, H; Parys, JB; Fissore,RA. Down-regulation of the inositol 1, 4, 5-triphosphate receptor in mouse eggs following fertilization or parthenogenetic activation. Dev. Biol. 2000 223, 238-250.
124. Lopez-Colome, AM; Lee,I. Pharmacological characterization of inositol-1,4,5,-triphosphate binding to membranes from retina and retinal cultures. J. Neuroscience Res. 1996 44, 149-156.
125. Poitras, M; Poirier, SN; Laflamme, K; Simoneau, M; Escher,E; Guillemette,G. Different populations of inositol 1,4,5-triphosphate receptors expressed in the bovine adrenal cortex. Receptors and Channels 2000 7, 41-52.
126. Thrower, EC; Duclohier, H; Edward, JA; Molle,G; Dawson,AP. The inositol 1,4,5-triphosphate-gated Ca2+ channel: effect of the protein thiol reagent thimerosal on channel activity. Biochem. J. 1996 318, 61-66.
127. Chen, L; Harada, N; Yamashita,T. Thimerosal-induced Ca2+ mobilization in isolated guinea pig cochlear outer hair cells. Acta Oto-Laryngologica Supplement 1998 539, 28-33.
128. Poirier, DN; Poitras, M; Laflamme, K; Guillemette,G. Thiol-reactive agents biphasically regulate inositol 1,4,5-triphosphate binding and Ca(2+) release activities in bovine adrenal cortex microsomes. Endocrinology 2001 142, 2614-2621.
129. Mezna, M; Michelangeli,F. Effects of thimerosal on the transient kinetics of 1,4,5-triphosphate-induced Ca2+ release from cerebellar microsomes. Biochem. J. 1997 325, 177-182.
130. Bultynck, G; Szlufcik, K; Sasri, NN; Assefa, Z; Callewaert, G; Missiaen, L; Parys, JB; DeSmedt,H. Thimerosal stimulates Ca2+ influx through inositol 1,4,5-triphosphate receptor type 1, but not type 3, via modulation of an isoform-specific Ca2+-dependent intramolecular interaction. Biochem. J. 2004 381, 87-96.
131. Mihai, R; Lai, T; Schofield, G; Farndon, JR. Thimerosal increases the responsiveness of the calcium receptor in human parathyroid and rMTC6-23 cells. Cell Calcium 1999 26, 95-101.
132. Butler, DM; Allen, KM; Garrett, FE; Lauzon, LL; Lotfizadeh, A; Koch,RA. Release of Ca(2+) from intracellular stores and entry of extracellular Ca(2+) are involved in sea squirt sperm activation. Dev. Biol. 1999 215, 453-464.
133. Ho, HC; Suarez,SS. An inositol 1,4,5-triphosphate receptor-gated intracellular Ca(2+) store is involved in regulating sperm hyperactivated motility. Biol. Reproduction 2001 65, 1606-1615.
134. Herrick, SB; Schweissinger, DL; Kim, SW; Bayan, KR; Mann, S; Cardullo,RA. The acrosomal vesicle of mouse sperm is a calcium store. J. Cell. Physiol. 2005 202, 663-671.
135. Malysz J; Donnelly, G; Huizinga, JD. Regulation of slow wave frequency by IP(3)-sensitive calcium release in the murine small intestine. Am. J. Physiol. Gastrointest.and Liver Physiol. 2001 280, G439-G448.
136. Nishio, H; Ken-ichi, N; Hirano, J; Nakata,Y. Effects of thimerosal, an organic sulfhydryl modifying agent, on serotonin transport activity into rabbit blood platelet. Neurochemistry International. 1996 29, 391-396.
137. Carey, MB; Matsumoto,SG. Calcium transient activity in cultured murine neural crest cells is regulated at the IP(3) receptor. Brain Res. 2000 862, 201-210.
138. Hidalgo, C; Aracena, P; Sanchez, G; Donoso,P. Redox regulation of calcium release in skeletal and cardiac muscle. Biol. Research. 2002 35, 13-3.
139. Young, KW; Pinnock, RD; Nahorski,SR. Determination of the inositol (1,4,5) triphosphate requirement for histamine-and substance P-induced Ca2+ mobilization in human U373 MG astrocytoma cells. Cell Calcium 1998 24, 59-70.
140. Abramson, JJ; Zable, AC; Favero, TG; Salama,G. Thimerosal interacts with the Ca2+ release channel ryanodine receptor from skeletal muscle sarcoplasmic reticulum. J. Biol. Chem. 1995 50, 29644-29647.
141. Tornquist, K; Vainio, P; Titievsky, A; Dugue, B; Tuominen,R. Redox modulation of intracellular free calcium concentration in thyroid FRTL-5 cells: evidence for an enhanced extrusion of calcium. Biochem. J. 1999 339, 621-628.
142. Sayers, LG; Brown, GR; Michell, RH; Michelangeli, F. The effects of thimerosal on calcium uptake and inositol 1,4,5-triphosphate-induced calcium release in cerebellar microsomes. Biochem. J. 1993 289, 883-887.
143. Jin,Y; Kim, DK; Khil, LY; Oh, U; Kim, J; Kwak, J. Thimerosal decreases TRPV1 activity by oxidation of extracellular sulfhydryl residues. Neurosci. Letters 2004 369, 250-255.
144. Linde, C; Loffler,C; Kessler, C; Quast, U. Interaction between thiol-modifying agents and P1075, a K(ATP) channel opener, in rat isolated aorta. Naunyn-Schmiedebergs Arch. Pharmacol: 1997 356, 467-474.
145. Sheu, SJ; Wu, SN. Mechanism of inhibitory actions of oxidizing agents on calciumactivated potassium current in cultured pigment epithelial cells of the human retina. Investigative Opthamalogy and Visual Sci. 2003 44, 1237-1244.
146. Evans, JR; Bielefeldt, K. Regulation of sodium currents through oxidation and reduction of thiol residues. Neuroscience 2000 101, 229-236.
147. Goppelt, M; Koerner, C-F; Hausman, Gesma, G; Resch, K. Control of prostanoid synthesis: role of reincorporation of released precursor fatty acids. Prostaglandins 1986 32, 373-385.
148. Norman, SJ; Poyser, NL. Effects of inhibitors of arachidonic acid turnover on the production of prostaglandins by the guinea-pig uterus. J. Reproduction and Fertility 2000 118, 181-186.
149. Iskit, AB; Guc,MO. Thimerosal attenuates ischaemia-reperfusion arrhythmias in rats: no modification by anti-ischaemic agent trimetazidine or endothelin receptor antagonist bosentan. Pharm. Res. 1996 34, 17-23.